W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

05 June, 2025

Communication of the meeting of Transparency Council No. 23/2025 on 2 June 2025

05 June, 2025

Communication of the meeting of Transparency Council No. 22/2025 on 26 May 2025

05 June, 2025

Communication of the meeting of Transparency Council No. 21/2025 on 19 May 2025

05 June, 2025

Communication of the meeting of Transparency Council No. 20/2025 on 13 May 2025

04 June, 2025

The Transparency Council meeting 24/2025 on 9 June 2025

03 June, 2025

Opinion of the Transparency Council – bosutinib and nilotinib

03 June, 2025

Opinion of the Transparency Council – bosutinib

03 June, 2025

Position of the Transparency Council – Vistogard (uridine triacetate)

03 June, 2025

Position of the Transparency Council – Keytruda (pembrolizumab)

03 June, 2025

Position of the Transparency Council – robotic thoracic surgery (lung cancer and other thoracic tumors)

03 June, 2025

Position of the Transparency Council – Raxone (idebenone)

03 June, 2025

Position of the Transparency Council – Kisqali (ribociclib)

30 May, 2025

The Transparency Council meeting 23/2025 on 2 June 2025

23 May, 2025

The Transparency Council meeting 22/2025 on 26 May 2025

19 May, 2025

The Transparency Council meeting 21/2025 on 19 May 2025 update

16 May, 2025

Communication of the meeting of Transparency Council No. 19/2025 on 12 May 2025

16 May, 2025

Opinion of the Transparency Council – valsartanum + indapamidum

16 May, 2025

Opinion of the Transparency Council – telmisartan + amlodipine besylate + hydrochlorothiazide

16 May, 2025

Opinion of the Transparency Council – pironolactonum, goserelinum, leuprorelinum

16 May, 2025

Position of the Transparency Council – EpiPen Jr. (epinephrine) and EpiPen Senior (epinephrine)

16 May, 2025

Position of the Transparency Council – Arexvy (recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted)

16 May, 2025

Position of the Transparency Council – Trimbow (beclometasone, formoterol, glycopyrronium bromide)

16 May, 2025

Position of the Transparency Council – Trimbow (beclometasone, formoterol, glycopyrronium bromide)

16 May, 2025

Opinion of the Transparency Council – Treatment of patients with acid sphingomyelinase deficiency (ASMD) type A/B and B

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑